entanglement in provings

1
LETTER TO THE EDITOR Entanglement in Provings I applaud the Walach et al for their attempts at applying quantitative methods to qualitative research 1 . Having myself conducted 70 homeopathic drug prov- ings following GCP guidelines, one with 110 subjects and an equal placebo group, I view this research as important in trying to evaluate whether or not it is possible, in a proving, to distinguish reliable symptoms specific to a medicine from random, non-specific symptoms. Many well-proven and commonly pre- scribed homeopathic remedies have ‘keynotes’ that did not appear in a homeopathic drug proving. However, I have some questions. Since we know that placebo symptoms in conventional medical research vary significantly across clinical trials for the same disease and also among different organ systems I am unclear how the authors concluded that what was experienced during the proving period was different from background noise. The sharp increase in both atypical and typical symptoms could be explained by the fact that subjects in this study went from a medicine free baseline period to a period of taking a homeopathic remedy. In addition the subjects were students in homeopathic schools which suggests that they may have been unusually sensitive to homeopathic remedies and, perhaps, suggestible and likely to experience symptoms during a proving. There was a trend for Cantharis to stimulate more symptoms typical of that remedy than atypical ones. If the typical Cantharis symptoms, as determined by the homeopathic expert, were symptoms commonly asso- ciated with non-specific or placebo responses then the increase in symptoms could be explained by other causes. The local and non-local hypotheses are also not mutually exclusive, both could operate at the same time and may be dependent on a variety of factors. Thank you for this thought provoking article. Reference 1 Walach H, Sherr J, Schneider R, Shabi R, Bond A, Rieberer G. Homeopathic proving symptoms: result of a local, non-local, or placebo process? A blinded, placebo-controlled pilot study. Homp 2004; 93: 179–185. David Riley E-mail address: [email protected] ARTICLE IN PRESS Reply to D Riley I am grateful to Dr Riley giving me the opportunity to explain some elements of our study more clearly. I agree with him: If the ‘‘typical’’ Cantharis symptoms, as determined by the homeopathic expert, were symptoms commonly associated with non- specific or placebo responses then the increase in symptoms could be explained by other causes. The problem here is the if. There is no way to determine which symptoms are specific for placebo, because there is no standard. Placebo can generate virtually any symp- tom. Hence, we have no external standard to answer this question, only the internal comparison within a given study. In our study, more symptoms typical for Cantharis were observed in both groups, compared to atypical symptoms. Bear in mind the following: the potential number of symptoms not typical for Cantharis, i.e. placebo symptoms, is unlimited, while the number of Cantharis symptoms is limited. Thus, baseline probability for a typical Cantharis symptom is very low compared to all other symptoms that could potentially be experienced. It is true that the symptoms could also be commonly associated with placebo responses, but in fact they were not. Symptoms were generally quite specific, and a lot of them were in the area of mind and dreams (possibly due to attention bias, or because this proving happened to be more effective in this area; incidentally one of the reasons Cantharis was not identified by the homeopathic expert was that it does not have an extensive mind-symptoms proving picture). But the Homeopathy (2005) 94, 69–70 r 2004 The Faculty of Homeopathy doi:10.1016/j.homp.2004.11.015, available online at http://www.sciencedirect.com

Upload: david-riley

Post on 27-Nov-2016

217 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Entanglement in Provings

ARTICLE IN PRESS

Homeopathy (2005) 94, 69–70r 2004 The Faculty of Homeopathy

doi:10.1016/j.homp.2004.11.015, available online at http://www.sciencedirect.com

LETTER TO THE EDITOR

Entanglement in Provings

I applaud the Walach et al for their attempts atapplying quantitative methods to qualitative research1.Having myself conducted 70 homeopathic drug prov-ings following GCP guidelines, one with 110 subjectsand an equal placebo group, I view this research asimportant in trying to evaluate whether or not it ispossible, in a proving, to distinguish reliable symptomsspecific to a medicine from random, non-specificsymptoms. Many well-proven and commonly pre-scribed homeopathic remedies have ‘keynotes’ thatdid not appear in a homeopathic drug proving.However, I have some questions. Since we know that

placebo symptoms in conventional medical researchvary significantly across clinical trials for the samedisease and also among different organ systems I amunclear how the authors concluded that what wasexperienced during the proving period was differentfrom background noise.The sharp increase in both atypical and typical

symptoms could be explained by the fact that subjectsin this study went from a medicine free baseline periodto a period of taking a homeopathic remedy. Inaddition the subjects were students in homeopathicschools which suggests that they may have been

Reply to D Riley

I am grateful to Dr Riley giving me the opportunity toexplain some elements of our study more clearly.I agree with him: If the ‘‘typical’’ Cantharissymptoms, as determined by the homeopathicexpert, were symptoms commonly associated with non-specific or placebo responses then the increase insymptoms could be explained by other causes. Theproblem here is the if. There is no way to determinewhich symptoms are specific for placebo, because there isno standard. Placebo can generate virtually any symp-tom. Hence, we have no external standard to answer thisquestion, only the internal comparison within a givenstudy. In our study, more symptoms typical for Canthariswere observed in both groups, compared to atypicalsymptoms.

unusually sensitive to homeopathic remedies and,perhaps, suggestible and likely to experience symptomsduring a proving.There was a trend for Cantharis to stimulate more

symptoms typical of that remedy than atypical ones. Ifthe typical Cantharis symptoms, as determined by thehomeopathic expert, were symptoms commonly asso-ciated with non-specific or placebo responses then theincrease in symptoms could be explained by othercauses.The local and non-local hypotheses are also not

mutually exclusive, both could operate at the sametime and may be dependent on a variety of factors.Thank you for this thought provoking article.

Reference

1 Walach H, Sherr J, Schneider R, Shabi R, Bond A, Rieberer G.

Homeopathic proving symptoms: result of a local, non-local, or

placebo process? A blinded, placebo-controlled pilot study.

Homp 2004; 93: 179–185.

David RileyE-mail address: [email protected]

Bear in mind the following: the potential number ofsymptoms not typical for Cantharis, i.e. placebosymptoms, is unlimited, while the number of Cantharissymptoms is limited. Thus, baseline probability for atypical Cantharis symptom is very low compared to allother symptoms that could potentially be experienced.It is true that the symptoms could also be commonlyassociated with placebo responses, but in fact theywere not. Symptoms were generally quite specific, anda lot of them were in the area of mind and dreams(possibly due to attention bias, or because this provinghappened to be more effective in this area; incidentallyone of the reasons Cantharis was not identified by thehomeopathic expert was that it does not have anextensive mind-symptoms proving picture). But the